We will be totally self-sufficient for the supply of medicines to American patients.” AstraZeneca CEO Pascal Soriot on the company’s plan to invest $50 billion in the U.S.

One of Trump's demands was that the CEOs' companies limit drug costs for states' Medicaid plans to "most-favored nation" ...

Today’s Forbes CFO newsletter focuses on Aradhana Sarin’s journey from treating patients to becoming what she calls a ...

President Donald Trump has given major pharmaceutical companies 60 days to slash prescription drug prices or face action.

With its latest $50 billion U.S. manufacturing investment and record U.S. growth, is British AstraZeneca looking at itself as ...

Pharmaceutical CEOs are on notice about sky-high drug prices as President Donald Trump demands a recalibration of what ...

AstraZeneca’s CEO said the company has proposed U.S. price cuts to some drugs, while Doximity enters competitive AI scribing ...

Good morning. Thirty-three days. That’s how long it took from the time AstraZeneca CEO Pascal Soriot greeted Virginia ...

In an earnings call on July 29th, in which the company reported a 13% increase in half-year profits, he said about Britain ...

AstraZeneca CEO Pascal Soriot said the U.K.-listed company had many reasons to be in the U.S., adding that it was “rapidly ...

The announcement of a 15% tariff on pharmaceutical imports to the U.S. from the European Union may have not been the ideal ...

Pascal Soriot's comments came during AstraZeneca's Q2 earnings call in regard to President Donald Trump’s newly announced ...